DNANYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Ginkgo Bioworks Holdings, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$10.07−0.20 (-1.95%)
Close on Oct 19, 2026
- Market cap
- $625.29M
- P/E (TTM)
- –
- Dividend yield
- –
Ginkgo Bioworks Holdings, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, TTM
- Gross margin
- –
- Operating margin
- -259.9%
- Net margin
- -260.0%
- Return on equity, FY2025
- -51.1%
Financial strength
- Current ratio
- 4.57
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 116.2%
Valuation
- P/E ratio
- –
- Price to sales
- 5.59
- Price to book
- 1.49
- Dividend yield
- –